共查询到20条相似文献,搜索用时 31 毫秒
1.
Sistiana Aiello Paola Cassis Marilena Mister Samantha Solini Federica Rocchetta Mauro Abbate Elena Gagliardini Ariela Benigni Giuseppe Remuzzi Marina Noris 《Transplant international》2011,24(8):829-838
Ischemia/reperfusion (I/R) injury is an important cause of renal graft dysfunction in humans. Increases in cold and warm ischemia times lead to a higher risk of early post‐transplant complications including delayed graft function and acute rejection. Moreover, prolonged cold ischemia is a predictor of long‐term kidney graft loss. The protective effect of rabbit anti‐rat thymocyte immunoglobulin (rATG) was evaluated in a rat model of I/R injury following syngeneic kidney transplantation. Serum creatinine concentration was evaluated at 16 h and 24 h post‐transplant. Animals were sacrificed 24 h post‐transplant for evaluation of histology, infiltrating leukocytes, nitrotyrosine staining, and apoptosis. rATG was effective in preventing renal function impairment, tissue damage and tubular apoptosis associated with I/R only when was given 2 h before transplantation but not at the time of reperfusion. Pretransplant rATG treatment of recipient animals effectively reduced the amount of macrophages, CD4+, CD8+ T cells and LFA‐1+ cells infiltrating renal graft subjected to cold ischemia as well as granzyme‐B expression within ischemic kidney. On the other hand, granulocyte infiltration and oxidative stress were not modified by rATG. If these results will be translated into the clinical setting, pretransplant administration of Thymoglobuline® could offer the additional advantage over peri‐transplant administration of limiting I/R‐mediated kidney graft damage. 相似文献
2.
Steven C. Kim David V. Mathews Cynthia P. Breeden Laura B. Higginbotham Joseph Ladowski Gregory Martens Allison Stephenson Alton B. Farris Elizabeth A. Strobert Joe Jenkins Eric M. Walters Christian P. Larsen Matthew Tector Alfred J. Tector Andrew B. Adams 《American journal of transplantation》2019,19(8):2174-2185
The shortage of available organs remains the greatest barrier to expanding access to transplant. Despite advances in genetic editing and immunosuppression, survival in experimental models of kidney xenotransplant has generally been limited to <100 days. We found that pretransplant selection of recipients with low titers of anti‐pig antibodies significantly improved survival in a pig‐to–rhesus macaque kidney transplant model (6 days vs median survival time 235 days). Immunosuppression included transient pan–T cell depletion and an anti‐CD154–based maintenance regimen. Selective depletion of CD4+ T cells but not CD8+ T cells resulted in long‐term survival (median survival time >400 days vs 6 days). These studies suggested that CD4+ T cells may have a more prominent role in xenograft rejection compared with CD8+ T cells. Although animals that received selective depletion of CD8+ T cells showed signs of early cellular rejection (marked CD4+ infiltrates), animals receiving selective CD4+ depletion exhibited normal biopsy results until late, when signs of chronic antibody rejection were present. In vitro study results suggested that rhesus CD4+ T cells required the presence of SLA class II to mount an effective proliferative response. The combination of low pretransplant anti‐pig antibody and CD4 depletion resulted in consistent, long‐term xenograft survival. 相似文献
3.
Ping Chen Qianmei Sun Yanfei Huang Mohamed G. Atta Sharon Turban Dorry L. Segev Kieren A. Marr Fizza F. Naqvi Nada Alachkar Edward S. Kraus Karl L. Womer 《Transplant international》2014,27(10):1069-1076
Reduced pretransplant blood myeloid dendritic cell (mDC) levels are associated with post‐transplant BK viremia and cytomegalovirus (CMV) disease after kidney transplantation. To elucidate potential mechanisms by which mDC levels might influence these outcomes, we studied the association of mDC levels with mDC IL‐12 production and T‐cell level/function. Peripheral blood (PB) was studied in three groups: (i) end stage renal disease patients on hemodialysis (HD; n = 81); (ii) chronic kidney disease stage IV‐V patients presenting for kidney transplant evaluation or the day of transplantation (Eval/Tx; n = 323); and (iii) healthy controls (HC; n = 22). Along with a statistically significant reduction in mDC levels, reduced CD8+ T‐cell levels were also demonstrated in the kidney disease groups compared with HC. Reduced PB mDC and monocyte‐derived DC (MoDC) IL‐12 production was observed after in vitro LPS stimulation in the HD versus HC groups. Finally, ELISpot assays demonstrated less robust CD3+ INF‐γ responses by MoDCs pulsed with CMV pp65 peptide from HD patients compared with HC. PB mDC level deficiency in patients with kidney disease is associated with deficient IL‐12 production and T‐cell level/function, which may explain the known correlation of CD8+ T‐cell lymphopenia with deficient post‐transplant antiviral responses. 相似文献
4.
Pretransplant CD4 Count Influences Immune Reconstitution and Risk of Infectious Complications in Human Immunodeficiency Virus–Infected Kidney Allograft Recipients
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. F. Suarez R. Rosa M. A. Lorio M. I. Morris L. M. Abbo J. Simkins G. Guerra D. Roth W. L. Kupin A. Mattiazzi G. Ciancio L. J. Chen G. W. Burke M. J. Goldstein P. Ruiz J. F. Camargo 《American journal of transplantation》2016,16(8):2463-2472
In current practice, human immunodeficiency virus–infected (HIV+) candidates with CD4 >200 cells/mm3 are eligible for kidney transplantation; however, the optimal pretransplant CD4 count above this threshold remains to be defined. We evaluated clinical outcomes in patients with baseline CD4 >350 and <350 cells/mm3 among 38 anti–thymocyte globulin (ATG)–treated HIV‐negative to HIV+ kidney transplants performed at our center between 2006 and 2013. Median follow‐up was 2.6 years. Rates of acute rejection and patient and graft survival were not different between groups. Occurrence of severe CD4 lymphopenia (<200 cells/mm3), however, was more common among patients with a baseline CD4 count 200–349 cells/mm3 compared with those transplanted at higher counts (75% vs. 30% at 4 weeks [p = 0.04] and 71% vs. 5% at 52 weeks [p = 0.001], respectively, after transplant). After adjusting for age, baseline CD4 count of 200–349 cells/mm3 was an independent predictor of severe CD4 lymphopenia at 4 weeks (relative risk [RR] 2.6; 95% confidence interval [CI] 1.3–5.1) and 52 weeks (RR 14.3; 95% CI 2–100.4) after transplant. Patients with CD4 <200 cells/mm3 at 4 weeks had higher probability of serious infections during first 6 months after transplant (19% vs. 50%; log‐rank p = 0.05). These findings suggest that ATG must be used with caution in HIV+ kidney allograft recipients with a pretransplant CD4 count <350 cells/mm3. 相似文献
5.
Qizhi Tang Joey Leung Kristin Melli Kimberly Lay Emmeline L. Chuu Weihong Liu Jeffrey A. Bluestone Sang‐Mo Kang V. Ram Peddi Flavio Vincenti 《Transplant international》2012,25(12):1257-1267
This study examined the effect of thymoglobulin induction therapy on leukocyte population dynamics in kidney transplant patients. Patients receiving standard immunosuppression were compared with those who received additional thymoglobulin at the time of kidney transplantation. Thymoglobulin induction led to an immediate and significant decrease of all T cells and NK cells, but not B cells or monocytes. CD8+ T cells recovered to near pretransplant level by 4 weeks post‐transplant. CD4+ T cells remained at less than 30% of pretransplant level for the entire study period of 78 weeks. Both CD4+ and CD8+ T cells showed reduced cytokine production after recovery. Deletion of CD4+FOXP3+HELIOS+ regulatory T cells (Tregs) was less profound than that of CD4+FOXP3? cells, thus the relative percentage of Tregs elevated significantly when compared with pretransplant levels in thymoglobulin‐treated patients. In contrast, the percentages of Tregs and their expression of FOXP3 in the standard immunosuppression group decreased steadily and by 12 weeks after transplant the average percentage of Tregs was 56% of the pretransplant level. Thus, thymoglobulin‐induced deletion of T cells led to significant and long‐lasting alterations of the T‐cell compartment characterized by a preservation of Tregs and long‐lasting reduction in CD4+, and potentially pathogenic, T cells. 相似文献
6.
Stauch D Yahyazadeh A Bova R Melloh GC Füldner A Baron U Olek S G?ldner K Weiss S Pratschke J Kotsch K 《Transplant international》2012,25(3):302-313
T‐cell‐depleting strategies are an integral part of immunosuppressive regimens used in the hematological and solid organ transplant setting. Besides prevention of alloreactivity, treatment with rabbit antithymocyte globulin (rATG) has been related to the induction of immunoregulatory T cells (Treg) in vitro and in vivo. To investigate Treg induced by rATG, we prospectively studied the effect of rATG induction therapy in liver‐transplanted recipients in vivo (n = 28). Treg induction was further evaluated by means of Treg‐specific demethylation region (TSDR) analysis within the FOXP3 locus. Whereas no induction of CD4+ CD25highCD127? Treg could be observed by phenotypic analysis, we could demonstrate an induction of TSDR+ T cells within CD4+ T cells exclusively for rATG‐treated patients in the long‐term (day 540) compared with controls (P = NS). Moreover, although in vitro experiments confirm that rATG primarily led to a conversion of CD4+ CD25? into CD4+ CD25+ T cells displaying immunosuppressive capacities, these cells cannot be classified as bona fide Treg based on their FOXP3 demethylation pattern. Consequently, the generation of Treg after rATG co‐incubation in vitro does not reflect the mechanisms of Treg induction in vivo and therefore the potential clinical relevance of these cells for transplant outcome remains to be determined. 相似文献
7.
Mario Fernández‐Ruiz Francisco López‐Medrano Luis M. Allende Amado Andrés Ana García‐Reyne Carlos Lumbreras Rafael San‐Juan José M. Morales Estela Paz‐Artal José M. Aguado 《Transplant international》2014,27(7):674-685
Serial monitoring of peripheral blood lymphocyte subpopulations (PBLSs) counts might be useful in predicting post‐transplant opportunistic infection (OI) after kidney transplantation (KT). PBLSs were prospectively measured in 304 KT recipients at baseline and post‐transplant months 1 and 6. Areas under receiver operating characteristic curves were used to evaluate the accuracy of different subpopulations in predicting the occurrence of overall OI and, specifically, cytomegalovirus (CMV) disease. We separately analyzed patients not receiving (n = 164) or receiving (n = 140) antithymocyte globulin (ATG) as induction therapy. In the non‐ATG group, a CD8+ T‐cell count at month 1 <0.100 × 103 cells/μl had negative predictive values of 0.84 and 0.86 for the subsequent occurrence of overall OI and CMV disease, respectively. In the multivariate Cox model, a CD8+ T‐cell count <0.100 × 103 cells/μl was an independent risk factor for OI (adjusted hazard ratio: 3.55; P‐value = 0.002). In the ATG group, a CD4+ T‐cell count at month 1 <0.050 × 103 cells/μl showed negative predictive values of 0.92 for the subsequent occurrence of overall OI and CMV disease. PBLSs monitoring effectively identify KT recipients at low risk of OI, providing an opportunity for individualizing post‐transplant prophylaxis practices. 相似文献
8.
《Transplantation proceedings》2019,51(6):1744-1753
IntroductionDepletion therapy in high immunologic risk (HR) patients by antithymocyte globulin (rATG) induces lymphopenia and subsequent compartmental repopulation of T-cell subsets. rATG is also given to patients receiving kidneys from donations after cardiac death (DCDs) to mitigate innate immune activation associated with the DCD process.MethodsWe compared the T-cell response with rATG in both HR and DCD kidney recipients. We examined the reconstitution of T-cell subsets after rATG treatment in HR and DCD recipients (n = 19 per group) by multicolor flow cytometry.ResultsFollowing treatment, there was a rapid drop in the frequency of T cells in both groups, which persisted over 28 days. HR patients had an early surge in the frequency of CD4+ naïve, effector-memory, and regulatory T cells. Although we found a significant proliferation of the T cells in both groups, the DCD cohort had a blunted response as well as reduced CD4+ T-cell immune-reactivity compare with the HR group.ConclusionsOur data suggest that there is a lack of significant homeostatic proliferative response in DCD recipients following rATG, and CD4+ T cells may be less reactive in the DCD group than previously thought, indicating that rATG treatment may not have to be considered a first-line induction therapy in DCD recipients. 相似文献
9.
S. Gurkan Y. Luan N. Dhillon S. R. Allam T. Montague J. S. Bromberg S. Ames S. Lerner Z. Ebcioglu V. Nair R. Dinavahi V. Sehgal P. Heeger B. Schroppel B. Murphy 《American journal of transplantation》2010,10(9):2132-2141
Depletional induction therapies are routinely used to prevent acute rejection and improve transplant outcome. The effects of depleting agents on T‐cell subsets and subsequent T‐cell reconstitution are incompletely defined. We used flow cytometry to examine the effects of rabbit antithymocyte globulin (rATG) on the peripheral T‐cell repertoire of pediatric and adult renal transplant recipients. We found that while rATG effectively depleted CD45RA+CD27+ naïve and CD45RO+CD27+ central memory CD4+ T cells, it had little effect on CD45RO+CD27? CD4+ effector memory or CD45RA+CD31?, CD45RO+CD27+ and CD45RO+CD27? CD8+ T cell subsets. When we performed a kinetic analysis of CD31+ recent thymic emigrants and CD45RA+/RO+ T cells, we found evidence for both thymopoiesis and homeostatic proliferation contributing to immune reconstitution. We additionally examined the impact of rATG on peripheral CD4+Foxp3+ T cells. We found that in adults, administration of rATG‐induced peripheral expansion and new thymic emigration of T cells with a Treg phenotype, while CD4+Foxp3+ T cells of thymic origin predominated in children, providing the first evidence that rATG induces Treg in vivo. Collectively our data indicate that rATG alters the balance of regulatory to memory effector T cells posttransplant, providing an explanation for how it positively impacts transplant outcome. 相似文献
10.
Marcella Franquesa Carla C. Baan Sander S. Korevaar Anja U. Engela Marieke Roemeling‐van Rhijn Willem Weimar Michiel G. H. Betjes Josep M. Grinyo Martin J. Hoogduijn 《Transplant international》2013,26(6):651-658
Mesenchymal stem cells (MSCs) possess immunomodulatory properties which are of key interest for their application in autoimmunity and transplantation. In transplantation, administration of MSCs has shown promising results in preclinical models and has recently moved to clinical trials. Therefore, it is important to study the interactions between MSCs and immunosuppressive drugs currently used in transplantation. We aimed to analyze the effect of rabbit antithymocyte globulin (rATG) MSCs. MSCs were obtained from perirenal fat of kidney donors and exposed to ranging doses of rATG (Thymoglobulin®, Genzyme; 0.5–100 μg/ml). Binding of rATG, effects on viability and susceptibility to be killed by cytotoxic lymphocytes as well as effects on their immunosuppressive potential of MSCs were tested. rATG binds dose‐dependently to MSCs. This binding was associated with slightly impaired viability after 48 and 72 h when compared with nonexposed MSCs. In contrast to nontreated MSCs, rATG preexposed MSCs were susceptible to be lysed by cytokine‐activated CD8+ cytotoxic cells and NKT cells. The capacity of MSCs to suppress the proliferation of anti‐CD3/CD28 activated CD4 and CD8 T cells were reduced by the presence of rATG in the culture. rATG reduces the viability and antiproliferative capacity of MSCs in a dose‐dependent manner and converts them into targets for CD8 T cells and NKT cell lysis. 相似文献
11.
Volker Daniel Cord Naujokat Mahmoud Sadeghi Fabrice Christoph Renner Rolf Weimer Gerhard Opelz 《Clinical transplantation》2010,24(2):281-289
Daniel V, Naujokat C, Sadeghi M, Renner FC, Weimer R, Opelz G. Association of high IFN‐γ plasma levels with low B‐cell counts in renal transplant recipients with stable long‐term graft function.Clin Transplant 2009 DOI: 10.1111/j.1399‐0012.2009.01067.x© 2009 John Wiley & Sons A/S. Abstract: Recently, we reported that patients with long‐term stable good graft function had higher interferon‐gamma (IFN‐γ) and lower IL‐4 plasma levels late as compared with early post‐transplant. These patients had more often detectable CD3+CD4+CD25+IFN‐γ+Foxp3+ peripheral blood lymphocytes (PBL) late post‐transplant than patients with impaired graft function. We therefore speculated that high plasma IFN‐γ late post‐transplant might contribute to the maintenance of graft acceptance. Using ELISA and four‐color flow cytometry, plasma cytokines and PBL subpopulations were measured in 65 renal transplant recipients with stable graft function late post‐transplant. High IFN‐γ plasma levels were associated with low CD19+ B PBL (r = ?0.329; p = 0.009) and low activated CD3+CD8+DR+ T PBL (r = ?0.266; p = 0.035). Plasma IFN‐γ increased with time post‐transplant (r = 0.288; p = 0.022) and was not associated with the dose of immunosuppressive drugs (p = n.s.). High plasma IFN‐γ was not associated with serum creatinine (r = 0.038; p = 0.765). Five patients showed evidence of chronic allograft nephropathy in previous biopsies and none of them exhibited increased plasma IFN‐γ. In patients with good long‐term graft function, high IFN‐γ plasma levels were associated with low numbers of B PBL and activated CD8+ T PBL. High IFN‐γ plasma levels might prevent the development of an immunological alloresponse and thereby contribute to the maintenance of graft acceptance. 相似文献
12.
Lymphoablation is routinely used in transplantation, and its success is defined by the balance of pathogenic versus protective T cells within reconstituted repertoire. While homeostatic proliferation and thymopoiesis may both cause T cell recovery during lymphopenia, the relative contributions of these mechanisms remain unclear. The goal of this study was to investigate the role of the thymus during T cell reconstitution in adult allograft recipients subjected to lymphoablative induction therapy. Compared with euthymic mice, thymectomized heart allograft recipients demonstrated severely impaired CD4 and CD8 T cell recovery and prolonged heart allograft survival after lymphoablation with murine anti‐thymocyte globulin (mATG). The injection with agonistic anti‐CD40 mAb or thymus transplantation only partially restored T cell reconstitution in mATG‐treated thymectomized mice. After mATG depletion, residual CD4 T cells migrated into the thymus and enhanced thymopoiesis. Conversely, depletion of CD4 T cells before lymphoablation inhibited thymopoiesis at the stage of CD4?CD8?CD44hiCD25+ immature thymocytes. This is the first demonstration that the thymus and peripheral CD4 T cells cooperate to ensure optimal T cell reconstitution after lymphoablation. Targeting thymopoiesis through manipulating functions of depletion‐resistant helper T cells may thus improve therapeutic benefits and minimize the risks of lymphoablation in clinical settings. 相似文献
13.
ATG‐Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
T. Crepin C. Carron C. Roubiou B. Gaugler E. Gaiffe D. Simula‐Faivre C. Ferrand P. Tiberghien J.‐M. Chalopin B. Moulin L. Frimat P. Rieu P. Saas D. Ducloux J. Bamoulid 《American journal of transplantation》2015,15(4):1028-1038
14.
Sewgobind VD van der Laan LJ Klepper M Ijzermans JN Tilanus HW Weimar W Baan CC 《Clinical transplantation》2008,22(5):579-586
Abstract: Background: The role of CD4+ CD25bright regulatory T cells (Treg) in controlling alloreactivity is established, but little is known whether antigen‐specific Treg are induced in fully immunosuppressed kidney transplant patients. Methods: The frequency and function of CD25bright T cells of nine stable kidney transplant patients before and 0.5–2 yr after transplantation were measured. Patients received triple therapy consisting of cyclosporine, mycophenolate mofetil and prednisone. To investigate the influence of transplantation and immunosuppression on Treg function, we compared their suppressive capacities pre‐ and post‐transplantation using mixed lymphocyte reactions and kept the CD25?/dim effector T‐cell (Teff) population constant. Results: After transplantation, the percentage of CD4+ CD25bright T cells significantly decreased from 8.5% pre‐transplant to 6.9% post‐transplant (median, p = 0.05). However, the lower percentage of post‐transplant CD4+ CD25bright T cells was not associated with reduced, but rather improved suppressor function of these cells. The proliferative response of pre‐transplant Teff to donor‐antigens was more profoundly suppressed by post‐transplant Treg than by pre‐transplant Treg (pre‐transplant 18% vs. post‐transplant 55% median, p = 0.03) and was comparable against third party antigens at a CD25bright:CD25?/dim ratio of 1:20. Conclusions: In immunosuppressed kidney transplant patients, the donor‐directed suppressive capacity of CD4+ CD25bright regulatory T cells improved, which may contribute to the development of donor‐specific hyporesponsiveness against the graft. 相似文献
15.
Pankewycz O Leca N Kohli R Wallace PK Said M Feng L Alnimri M Patel S Laftavi MR 《Transplantation proceedings》2011,43(2):462-465
Rabbit antithymocyte globulin therapy (rATG) is a potent lymphocyte-depleting agent commonly used following renal transplantation to reduce the risk of acute rejection. Standard doses (7-10 mg/kg) of rATG result in profound lymphopenia and predispose patients to infection and malignancy. The effects of lower doses of rATG (LoD-rATG, 3-5 mg/kg) on peripheral blood lymphocytes (PBL) are as yet unknown. In this prospective clinical trial, PBL subsets were characterized by flow cytometry over 12 months following LoD-rATG therapy. All patients were initially treated with standard doses of tacrolimus, mycophenolic acid, and prednisone. At 3 months, patients were randomized to either lower doses of tacrolimus or sirolimus to examine the effects of maintenance immunosuppression on PBL reemergence. LoD-rATG therapy resulted in prolonged suppression of CD19+ B cells, total CD3+ T cells, as well as naïve and memory CD4+ T cell and CD4/CD25/Foxp3+ T-regulatory subsets irrespective of chronic immunosuppressive therapy. Selective depletion was only noted in the CD4CD45RA+ naïve T-cell subset resulting in an altered memory/naïve CD4+ ratio. LoD-rATG failed to deplete CD8+ T cells, which increased their relative contribution to the total CD3+ pool. All other lymphocyte subsets maintained near normal proportions. Thus, LoD-rATG therapy may lessen the adverse effects of full dose rATG while maintaining overall efficacy. 相似文献
16.
Ildefonso Espigado Fátima de la Cruz‐Vicente Omar J. BenMarzouk‐Hidalgo Irene Gracia‐Ahufinger Jose R. Garcia‐Lozano Manuela Aguilar‐Guisado Jose M. Cisneros Alvaro Urbano‐Ispizua Pilar Perez‐Romero 《Transplant international》2014,27(12):1253-1262
The aim of this study was to characterize timing, kinetic, and magnitude of CMV‐specific immune response after hematopoietic stem cell transplantation (HSCT) and its ability to predict CMV replication and clinical outcomes. Using cell surface and intracellular cytokine staining by flow cytometry, CMV‐specific T‐cell response was measured in blood, while CMV viral load and chimerism were determined by real‐time PCR. Patients that reconstituted CMV‐specific T‐cell response within 6 weeks after Allo‐SCT showed a more robust immune response (CD8+: 0.7 cells/μl vs. 0.3/μl; P‐value = 0.01), less incidence of CMV replication (33% vs. 89.5%; P‐value = 0.007), reduced viral loads (1.81 log copies/ml vs. 0 copies/ml; P‐value = 0.04), and better overall survival (72%; CI: 0.53–0.96 vs. 42% CI: 0.24–0.71; P‐value = 0.07) than patients with a delayed immune reconstitution. Viremic patients had significantly higher transplant‐related mortality than nonviremic patients after 1 year (33% CI: 0.15–0.52 vs. 0% CI: 0.05–0.34; P‐value = 0.01). Risk factors independently associated with viral replication were receptor pretransplant CMV‐positive serostatus (P‐value = 0.02) and acquiring CMV‐specific T‐cell response after 6 weeks post‐transplantation (P‐value = 0.009). In conclusion, timing of acquiring a positive CMV‐specific T‐cell immune response after transplantation may identify patients with different risk for viral replication and different clinical outcomes, including survival. 相似文献
17.
E. J. Ramos H. S. Pollinger M. D. Stegall J. M. Gloor A. Dogan J. P. Grande 《American journal of transplantation》2007,7(2):402-407
Rituximab, intravenous immunoglobulin (IVIG) and rabbit antithymocyte globulin (rATG) all have been suggested to have an effect on antibody producing cells, however, supporting data are lacking. To assess the impact of these agents on splenic B‐cell populations in vivo, we retrospectively examined 25 spleens removed from patients treated with these agents as part of desensitization protocols in either ABO incompatible or positive crossmatch living donor kidney transplantation. These were compared to control (CTL) spleens removed for trauma. CTLs and spleens removed at transplant after multiple pretransplant plasmaphereses (PP) plus low‐dose IVIG showed similar large numbers of naïve B cells (CD20+ and CD79+), plasma cells (CD138+) and memory B cells (CD27+ cells). Adding rituximab to this PP/IVIG regimen reduced the number naïve B cells, but had no effect on memory or plasma cells. Combination treatment (PP/IVIG, rituximab and rATG) showed a trend toward the reduction of CD27+ cells, but again plasma cells were unchanged. We conclude that none of these protocols reduces splenic plasma cells in vivo. PP/low‐dose IVIG does not alter splenic B cells, but the addition of rituximab decreases mature B cells. Memory B cells may be affected by combination therapy including rATG and requires further study. 相似文献
18.
Ernesto Paoletti Elisabetta Bussalino Diego Bellino Augusto Tagliamacco Marco Bruzzone Maura Ravera Angelica Parodi Iris Fontana Gabriele Gaggero Giacomo Garibotto Jean Louis Ravetti 《Clinical transplantation》2019,33(6)
Macrophage infiltration is associated with unfavorable kidney graft outcome in protocol biopsies, but few studies have evaluated its impact on clinical practice. We therefore prospectively evaluated 37 kidney transplant recipients (KTRs) who underwent kidney biopsy due to slight increases in serum creatinine, or mild proteinuria (>0.3 g/24 hr), in the first post‐transplant year. Banff score, CD68+ count (score 0‐3) by immunohistochemistry, and 1‐year DSA were assessed. DGF was reported in 10 (27%) patients, 6 (16%) had normal biopsy, 7 (19%) borderline lesions, 13 (35%) IFTA, and 11 (30%) other lesions. Fifteen KTRs had grade 3 CD68+ infiltration, and 47% developed de novo DSA. During a 6.2 ± 2.7 year follow‐up, four patients (11%) suffered from biopsy‐proven T‐cell rejection, 17 KTRs (46%) lost their graft (12 in the grade 3 CD68+ group). Graft survival was lower in KTRs with grade 3 CD68+ infiltration (P = 0.0074; log‐rank test). Grade 3 CD68+ infiltrate was an independent predictor of graft loss (HR 5.41, 95% CI 1.74‐16.8; P = 0.003), together with more severe graft dysfunction at biopsy (HR 6.41, 95% CI 2.57‐16; P < 0.001). We conclude that grade 3 CD68+ interstitial infiltration is associated with increased risk of subsequent graft loss independent of other factors. 相似文献
19.
Ruud W. J. Meijers Nicolle H. R. Litjens Elly A. de Wit Anton W. Langerak Carla C. Baan Michiel G. H. Betjes 《Transplant international》2014,27(12):1272-1284
The uremia‐induced inflammatory environment in end‐stage renal disease (ESRD) patients is associated with premature T‐cell aging resulting in a defective T‐cell immunity. As kidney transplantation (KTx) reduces the pro‐inflammatory environment, we hypothesized that KTx would rejuvenate the aged T‐cell system. As aging parameters, we determined in 70 KTx recipients the differentiation status by immunophenotyping, thymic output by the T‐cell receptor excision circle (TREC) content together with CD31+ naïve T‐cell numbers and the relative telomere length (RTL) as a measure for proliferative history at pre‐KTx, 3, 6 and 12 months post‐KTx. In addition, T‐cell function was determined by measuring the proliferative capacity and percentages of cytokine‐producing cells. Directly post‐KTx, memory T‐cell numbers were diminished but restored to pre‐KTx values at 12 months, except for CD4+EM T cells. The RTL of (memory) CD4+ and CD8+ T cells did not change. In contrast, TREC content and CD31+ naïve T‐cell numbers were stable post‐KTx although the RTL of naïve CD4+ and CD8+ T cells decreased implying homeostatic proliferation of naïve cells, in response to a temporary decrease in memory cells. The T‐cell function was not improved post‐KTx. Our findings demonstrate that the uremia‐associated aged phenotype is stably imprinted in the T‐cell system and not reversed by KTx. 相似文献
20.
Martino Introna Marta Todeschini Regiane Aparecida Cavinato Chiara Capelli Alessandro Rambaldi Paola Cassis Paola Rizzo Monica Cortinovis Marina Noris Giuseppe Remuzzi 《Transplant international》2013,26(9):867-878
Bone marrow‐derived mesenchymal stromal cells (MSC) have emerged as useful cell population for immunomodulation therapy in transplantation. Moving this concept towards clinical application, however, should be critically assessed by a tailor‐made step‐wise approach. Here, we report results of the second step of the multistep MSC‐based clinical protocol in kidney transplantation. We examined in two living‐related kidney transplant recipients whether: (i) pre‐transplant (DAY‐1) infusion of autologous MSC protected from the development of acute graft dysfunction previously reported in patients given MSC post‐transplant, (ii) avoiding basiliximab in the induction regimen improved the MSC‐induced Treg expansion previously reported with therapy including this anti‐CD25‐antibody. In patient 3, MSC treatment was uneventful and graft function remained normal during 1 year follow‐up. In patient 4, acute cellular rejection occurred 2 weeks post‐transplant. Both patients had excellent graft function at the last observation. Circulating memory CD8+ T cells and donor‐specific CD8+ T‐cell cytolytic response were reduced in MSC‐treated patients, not in transplant controls not given MSC. CD4+FoxP3+Treg expansion was comparable in MSC‐treated patients with or without basiliximab induction. Thus, pre‐transplant MSC no longer negatively affect kidney graft at least to the point of impairing graft function, and maintained MSC‐immunomodulatory properties. Induction therapy without basiliximab does not offer any advantage on CD4+FoxP3+Treg expansion ( ClinicalTrials.gov number: NCT 00752479). 相似文献